Why Is Cooper Companies (COO) Stock Down -15.56% Today?
Key Takeaways
- COO shares fell roughly 15.56% in Thursday trading, extending a slide that began after Wednesday's closing bell.
- The primary catalyst was fiscal Q3 2026 revenue that missed estimates, compounded by sharply reduced Q4 and full-year guidance.
- Management cited ongoing U.S. channel inventory destocking at its CooperVision contact-lens unit as the main drag.
- The company also concluded a months-long strategic review and chose to retain CooperSurgical rather than sell it.
- A wave of analyst downgrades and price-target cuts amplified the selling pressure.
- Traders are now watching whether CooperVision's inventory reset stabilizes heading into fiscal 2027.
Opening Summary
The Cooper Companies, Inc. (COO), a medical-device maker operating through its CooperVision contact-lens business and CooperSurgical women's-health and fertility unit, saw its shares plunge on Thursday. The stock traded near $53.60, down $9.88 from the prior session's close of $63.48, a decline of roughly 15.56%. The selloff was driven by a disappointing fiscal third-quarter earnings report and guidance cut announced after the market closed on Wednesday, which markets interpreted as a sign of weakening momentum in the company's core vision-care franchise.
Earnings Results and Guidance Cut
For the fiscal third quarter ended July 31, 2026, Cooper Companies reported revenue of approximately $1.07 billion, below the roughly $1.10 billion Wall Street consensus and up only about 1% year over year. Adjusted earnings per share came in at $1.15, modestly ahead of the $1.12 estimate. The earnings beat, however, was overshadowed by the top-line shortfall and, more importantly, a forward outlook that fell well short of expectations.
Management guided fourth-quarter revenue to between $1.057 billion and $1.08 billion, implying organic growth of just 0% to 2%, and fourth-quarter adjusted EPS of $1.05 to $1.09, well below the consensus near $1.19 to $1.20. Full-year fiscal 2026 revenue guidance was cut to $4.23 billion to $4.25 billion from $4.29 billion to $4.32 billion, while full-year adjusted EPS guidance was lowered to $4.51 to $4.55 from $4.58 to $4.66. The revision marked the fourth guidance reduction in roughly two years, a pattern that has steadily eroded investor confidence.
CooperVision Inventory Destocking
The core of the problem was concentrated in CooperVision, which generates the majority of company revenue. Segment sales were flat year over year, with the Americas posting an organic decline. Executives attributed the weakness to an intentional reduction in U.S. distribution-channel inventory, a dynamic they said would continue to pressure results through the fiscal fourth quarter. While management expects the destocking to be largely complete entering fiscal 2027, the near-term reset leaves growth unusually muted at a business investors had counted on for steadier expansion. CooperSurgical, by contrast, posted modest growth and steady fertility demand, but was not enough to offset the vision-care shortfall.
Strategic Review Concludes With No Divestiture
Adding to the pressure, the company announced the conclusion of a strategic review it began in December 2025, revealing that its board had unanimously decided to retain CooperSurgical rather than pursue a sale. The board concluded that offers received did not adequately reflect the unit's value, partly reflecting new competition in the non-hormonal intrauterine device market. While management framed the decision as value-maximizing, some investors had anticipated a divestiture as a potential catalyst to unlock shareholder value, and the announcement contributed to the day's decline. The company did expand its share-repurchase authorization from $2 billion to $3 billion and reported record quarterly free cash flow of about $273 million, but those positives were outweighed by the weaker outlook.
Analyst Downgrades and Market Reaction
The guidance reset triggered a rapid round of sell-side downgrades. Piper Sandler cut the stock to Neutral from Overweight and slashed its price target to $59 from $86, while Baird moved to Neutral from Outperform, reducing its target to $61 from $85. BofA Securities downgraded the shares to Neutral from Buy, and Wells Fargo and Needham trimmed their price targets as well. The combination of the revenue miss, the reduced guidance, and the retained CooperSurgical decision created what analysts described as multiple simultaneous negative catalysts, pushing shares toward multi-year lows.
Market Context and Trading Activity
Trading volume surged to several times the stock's typical daily average as investors repriced the shares, reflecting heavy institutional repositioning. The decline was company-specific rather than a reflection of broader market conditions: major equity indices were mixed, with the S&P 500 and Dow Jones modestly higher in early trading, indicating the move was not driven by a sector-wide or macroeconomic selloff. The stock also broke decisively below recent support levels, trading near its 52-week low and deepening a year-to-date decline that had already exceeded 20%.
What Comes Next for COO
Investors will be watching closely whether CooperVision's U.S. channel-inventory reset concludes as planned and whether organic growth reaccelerates in fiscal 2027. The company's fourth-quarter results, expected later in the fiscal year, will provide the first concrete evidence of whether the destocking headwinds are abating. Analysts will also monitor the pace of margin recovery and the impact of a higher anticipated tax rate on next year's earnings growth. Key risks include continued competitive pressure in the vision-care market, new entrants in the intrauterine device space affecting CooperSurgical, and execution uncertainty following the strategic review. Until management demonstrates stabilization in its core franchise, the stock is likely to remain volatile.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots designed to navigate shifting market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current conditions are featured in this section. Bots vary by strategy, timeframe, performance metrics, and traded symbols, giving traders a range of approaches to explore. Discover which strategies are currently leading the market by visiting the Trending AI Robots page.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
COO's RSI Indicator remains in oversold zone for 1 day
It is expected that a price bounce should occur soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where COO advanced for three days, in of 271 cases, the price rose further within the following month. The odds of a continued upward trend are .
COO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 213 cases where COO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on August 24, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on COO as a result. In of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for COO turned negative on August 20, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at .
COO moved below its 50-day moving average on August 27, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for COO crossed bearishly below the 50-day moving average on September 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where COO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.489) is normal, around the industry mean (5.001). P/E Ratio (21.856) is within average values for comparable stocks, (142.833). Projected Growth (PEG Ratio) (0.603) is also within normal values, averaging (3.231). Dividend Yield (0.000) settles around the average of (0.015) among similar stocks. P/S Ratio (2.941) is also within normal values, averaging (74.467).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. COO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. COO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a maker of medical devices
Industry PharmaceuticalsOther
Advertisement